Sanofi India faces ₹2.37 Crore tax demand from Tiruvallur Commercial Tax Officer
Sanofi India Limited received an order for FY 2021-22 determining a total tax demand of ₹2.37 crore. This includes ₹1.34 crore tax, ₹0.89 crore interest, and ₹0.13 crore penalty. The demand is related to Input Tax Credit eligibility. The company plans to appeal the order.
The tax demand of ₹2.37 crore, while significant, is unlikely to have a material impact on the overall financial health of a large company like Sanofi India, but it does require an appeal process and potential financial outflow.
The company has been issued a tax demand with penalties and interest, which is a negative financial development.
Sanofi India Limited has received an order from the Office of the Commercial Tax Officer, Tiruvallur, Tamil Nadu, for the Financial Year 2021-22.
The order determines a total tax demand of ₹2,37,02,854, which includes ₹1,34,27,399 in tax, ₹89,32,714 in interest, and ₹13,42,741 in penalty. This demand arises from the dismissal of the company's submissions regarding the eligibility of Input Tax Credit (ITC) for FY 2020-21, which was claimed in FY 2021-22.
The company received the order dated 30th December 2025 on 19th February 2026. Sanofi India Limited intends to appeal this order before the Appellate Authorities.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.